| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Q5160 | Bevacizumab-nwgd (Jobevne) | Jobevne | 10mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2025 | Jan 1, 2026 | In Use | ||
| J9033 | Bendamustine Hcl | Bendamustine Hcl | 1 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2008 | Jan 1, 2009 | In Use | ||
| J9039 | Blinatumomab | Blincyto | 1 mcg | Immunotherapy | Monoclonal Antibody | CD3 (T cells) and CD19 (B cells) | No | 2014 | Jan 1, 2016 | In Use | ||
| C9308 | Carboplatin (avyxa) | Kyxata | 1mg | Chemotherapy | Alkylating Agent | Platinum Compound | No | 2025 | Jan 1, 2026 | In Use | ||
| NA | Bicalutamide | Casodex | 50 mg | Hormonal Therapy | Androgen Receptor Inhibitor | non-steriodal | Yes | 1995 | In Use | |||
| J9999 | Chemotherapy - non specific | Not otherwise classified, antineoplastic drugs | NA | Chemotherapy | No | In Use | ||||||
| Q5118 | Bevacizumab-bvzr | Zirabev | 10mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2019 | Oct 1, 2019 | In Use | ||
| J9075 | Cyclophosphamide (nos) | Cyclophosphamide (nos) | 5mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1959 | Apr 17, 2024 | In Use | ||
| NA | Cyclosporine | NeOral | 25mg, 100mg | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Yes | 1995 | In Use | |||
| NA | Cyclosporine | Sandimmune | 25mg, 50mg, 100mg | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Yes | 1983 | In Use | |||
| NA | Dacomitinib | Vizimpro | 15mg, 30mg, 45mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2018 | In Use | |||
| C9012 | Arsenic Trioxide | Trisenox | unspecified | Chemotherapy | Miscellaneous Agent | PML/RARa | No | 2000 | Jan 1, 2001 | Dec 31, 2001 | No Longer Used | |
| J9140 | Dacarbazine | Dacarbazine | 200 mg | Chemotherapy | Alkylating Agent | Purine Analog | No | 1975 | Jan 1, 1994 | Dec 31, 2010 | No Longer Used | |
| Q2057 | Afamitresgene autoleucel | Tecelra | per therapeutic dose | Immunotherapy | T Cell Receptor (TCR) | MAGE-A4 | No | 2024 | Mar 26, 2025 | In Use | ||
| C9491 | Avelumab | Bavencio | 10 mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2017 | Oct 1, 2017 | In Use | ||
| Q2041 | Axicabtagene Ciloleucel | Yescarta | Up to 200 million | Immunotherapy | CAR-T | CD19 | No | 2017 | Jan 1, 2019 | In Use | ||
| Q5126 | Bevacizumab-maly | Alymsys | 10mg | Immunotherapy | Monoclonal Antibody | VEGF | No | 2022 | Nov 28, 2022 | In Use | ||
| C9096 | Filgrastim | Releuko | 1mcg | Ancillary Therapy | Immunostimulant | Granulocyte colony stimulating factor | No | 2022 | Mar 25, 2022 | Sep 27, 2022 | No Longer Used | |
| NA | Acalabrutinib | Calquence | 100 mg | Chemotherapy | Tyrosine Kinase Inhibitor | Bruton's Tyrosine Kinase (Btk) /BCR | Yes | 2017 | In Use | |||
| NA | Anastrozole | Arimidex | 0.5 mg | Hormonal Therapy | Aromatase Inhibitor | Yes | 1995 | In Use | ||||
| J9180 | Epirubicin | Epirubicin | 50 mg | Chemotherapy | Antitumor Antibiotic | Anthracycline | No | 1999 | Jan 1, 2001 | Dec 31, 2003 | No Longer Used | |
| J9328 | Temozolomide | Temodar | 1 mg | Chemotherapy | Alkylating Agent | Tetrazine | No | 1999 | Jan 1, 2010 | In Use | ||
| NA | Cysteamine Bitartrate | Cystagon | 50mg, 150mg | Chemotherapy | Cystine-Depleting Agent | Yes | 1994 | In Use | ||||
| J9024 | Atezolizumab, hyaluronidase-tqjs | Tecentriq Hybreza | 5mg | Immunotherapy | Checkpoint Inhibitor | PD-L1 | No | 2024 | Mar 26, 2025 | In Use | ||
| J8999 | Chemotherapy - non specific | Prescription drug, oral, chemotherapeutic NOS | NA | Chemotherapy | Yes | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home